Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement

 
• By Derrick Gingery

Settlement with US government also includes $225m payment to resolve criminal and civil cases related to illegal marketing of the sublingual fentanyl spray Subsys.

LISBON, PORTUGAL - December 9, 2014: Photo of the United States Department of Justice (DOJ) homepage on a monitor screen through a magnifying glass.
Insys must exit the opioid space as part of a corporate integrity agreement negotiated with the US Justice and Health and Human Services departments. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance